98. Eosinophilic gastrointestinal disease
128 clinical trials,   147 drugs   (DrugBank: 40 drugs),   34 drug target genes,   132 drug target pathways

Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004391-19-NL
(EUCTR)
30/07/202013/05/2020Study to Evaluate the Efficacy and Safety of AK002 in Patients with Active Eosinophilic EsophagitisA Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safetyof AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis Active Eosinophilic Esophagitis (EoE)
MedDRA version: 20.0;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Antolimab
Product Code: AK002
INN or Proposed INN: Antolimab
Allakos Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 2;Phase 3United States;Australia;Netherlands